< Back to latest news & events

Blogs

Agritech Thymes: The Bite of Implied Consent: Lessons from the Pink Lady Case

October 2025

  • Can the supply of a plant variety without clear and defined restrictions on its use be an implicit consent to commercialise it?

This case centres on the evidence required to establish “serious doubts” regarding novelty of the well-known Cripps Pink (“Pink Lady”) and Cripps Red (“Sundowner”) apple varieties. As a reminder, novelty of a plant variety right is assessed using a test of “commercial novelty”, rather than a test of “absolute novelty” as used in patent law.

The EU General Court decision (T-159/24) reaffirms that implicit consent to commercialise a plant variety can undermine its EU plant variety right (CPVR) protection.  The Court decided that the supply of varieties to nurseries without clear restrictions as regards their use long before filing the CPVR applications was enough to provide implicit consent to exploit them commercially, to the detriment of their EU plant variety rights.

The takeaway? Even if the intention is merely to hand out new varieties for testing purposes in commercially relevant field trials, it is best to expressly limit the use of new varieties for testing or research purposes to preserve their novelty in a subsequent CPVR application.

The Court also addressed the role of declarations as evidence. It confirmed that declarations may carry weight even without supporting documentation, provided they’re credible, made by impartial parties, and consistent with other evidence.

In short, record-keeping and express limitations regarding commercial uses in contracts are key. Creators of new varieties should document when varieties are disposed of and retain evidence of any use restrictions placed on those varieties to mitigate the possibility of a third party establishing “serious doubts” regarding the novelty of the variety.

Click the button below to read our full article.

Latest updates

Doubling Up on Added Matter at the UPC

Following the UPC Court of Appeal (CoA) decision in Abbott v Sibio (APL_39664/2024, 14 February 2025) we now have a second CoA decision on added matter in expert Klein v …

Read article
Event - 4th November 2025

HGF are Silver Sponsors of LSPN Europe 2025

HGF is proud to be a Silver Sponsor of LSPN Europe 2025, a leading forum dedicated to helping life sciences innovators protect and leverage their intellectual property across the entire …

Event details
Event - 30th - 31st October 2025

RAPS European Digital Technologies and Software conference

HGF is proud to be attending the RAPS European Digital Technologies and Software conference in The Netherlands on 30th-31st October. HGF Partner and Patent Attorney Janine Swarbrick and Patent Director …

Event details

Protect It Before You Promote It: IP Advice for MedTech Innovators

Developed a new medical product? Check. Got tickets to an exciting MedTech conference to show off your new product? Check. Intellectual property? Pardon? In the excitement of bringing a new …

Read article

Agritech Thymes: The Bite of Implied Consent: Lessons from the Pink Lady Case

Can the supply of a plant variety without clear and defined restrictions on its use be an implicit consent to commercialise it? This case centres on the evidence required to …

Read article

IAM Global Leaders 2026

HGF is proud to announce that we have 3 partners listed as an IAM Global Leader 2026. To qualify for inclusion in the IAM Global Leaders, individuals must be ranked …

Read article

The Bite of Implied Consent: Lessons from the Pink Lady Case

A recent European Union court decision considers the issue of implied consent to commercialise a plant variety, and whether the evidence meets the threshold of “serious doubts” of the validity …

Read article
Event - 5th November 2025

HGF are Gold Sponsors of IAM Live: Navigating the UPC 2025

We’re excited to share that HGF is a Gold Sponsor of IAM Live: Navigating the UPC 2025, taking place on the 5th November at the Marriott Opera Ambassador Hotel in …

Event details